A Once-in-a-Decade Opportunity: 2 Magnificent Dividend Stocks Down 34% to 52% I'm Buying Right Now

Zoetis is down 52% from its 52-week high and Badger Meter is down 34%, with the article arguing both sell-offs create long-term buying opportunities despite recent sales weakness. Zoetis reported a 1% decline in organic sales and 4% EPS growth last quarter, trades at 13 times FCF, yields 3%, and repurchased 8% of its shares over the past year. Badger Meter's sales declined in each of its two most recent quarters after strong prior growth; it trades at 29 times earnings and 24 times FCF, with a 1.3% dividend yield and long-term growth potential from water-infrastructure modernization.

Analysis

The article’s key assumption is that weak results at both companies are timing noise. That is more testable at Badger Meter than at Zoetis: BMI’s project handoffs should eventually show up in orders and revenue, while Zoetis needs evidence that product adoption and veterinary demand can recover. A shift toward SaaS could improve BMI’s revenue visibility, but only if recurring revenue grows without being offset by delayed utility projects or weaker hardware demand. Municipal procurement and rate pressure are the key near-term constraints; Xylem is a relevant water-infrastructure peer, though the article gives no basis to infer relative valuation or exposure.

For ZTS, a low price-to-FCF multiple is not automatically a floor if current FCF is temporarily elevated or the stalled osteoarthritis opportunity was important to growth expectations. Elanco and Merck’s animal-health businesses are competitive reference points, but the supplied data do not establish comparative product momentum. Buybacks may support per-share results, yet can also use cash that investors would prefer to see invested in R&D if pipeline returns disappoint.

Near term, both stocks remain vulnerable to estimate cuts. Over 1–3 months, watch BMI project conversion and ZTS U.S. veterinary demand and product uptake. Over 6–18 months, the thesis depends on recurring-revenue mix at BMI and credible launches at ZTS. The contrarian risk: the market may be discounting normalized growth rather than overreacting to a temporary dip. Verify valuation and FCF definitions, order/backlog trends, and the source and sustainability of reported buybacks before sizing positions.

Key Decisions for Investors

• ZTS: Consider a staged long rather than buying the full position immediately; add only if veterinary demand stabilizes and new-product adoption supports guidance. Falsify the thesis on further material guidance cuts, continued organic-sales weakness, or evidence that pipeline launches are delayed or commercially weak.
• BMI: Keep on an evidence-triggered watchlist instead of assuming the project lull is temporary. Add after new project launches translate into improving orders/revenue and SaaS growth is separately visible; reassess if declines persist or project timing pushes out again.
• Prefer ZTS as the initial watchlist candidate for a dividend-oriented recovery thesis, but do not treat the stated valuation multiples as independently verified. Check current FCF, earnings quality, and management’s capital-allocation plans before entry.
• Avoid a forced short or options trade: the article offers no catalyst date or position-level data to support one. Revisit after the next earnings reports, using guidance revisions and project/pipeline conversion as the decision points.